Regular review - Drug treatment of multiple sclerosis

被引：46

作者：

Polman, CH ^{[1
]}

Uitdehaag, BMJ ^{[1
]}

机构：

[1] Vrije Univ Amsterdam, Acad Hosp, Dept Neurol, NL-1007 MB Amsterdam, Netherlands

来源：

BRITISH MEDICAL JOURNAL | 2000年 / 321卷 / 7259期

关键词：

D O I：

10.1136/bmj.321.7259.490

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：490 / 494

页数：5

共 29 条

[1] Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis [J].

Barnes, D ;

Hughes, RAC ;

Morris, RW ;

WadeJones, O ;

Brown, P ;

Britton, T ;

Francis, DA ;

Perkin, GD ;

Rudge, P ;

Swash, M ;

Katifi, H ;

Farmer, S ;

Frankel, J .

LANCET, 1997, 349 (9056) :902-906

[2]

Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO

[3]

2-#

[4]

Comi G, 1999, NEUROLOGY, V52, pA289

[5]

COMI G, 1995, MULT SCLER, V1, P24

[6] INTERFERON BETA-1B IS EFFECTIVE IN RELAPSING-REMITTING MULTIPLE-SCLEROSIS - CLINICAL-RESULTS OF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].

DUQUETTE, P ;

GIRARD, M ;

DESPAULT, L ;

DUBOIS, R ;

KNOBLER, RL ;

LUBLIN, FD ;

KELLEY, L ;

FRANCIS, GS ;

LAPIERRE, Y ;

ANTEL, J ;

FREEDMAN, M ;

HUM, S ;

GREENSTEIN, JI ;

MISHRA, B ;

MULDOON, J ;

WHITAKER, JN ;

EVANS, BK ;

LAYTON, B ;

SIBLEY, WA ;

LAGUNA, J ;

KRIKAWA, J ;

PATY, DW ;

OGER, JJ ;

KASTRUKOFF, LF ;

MOORE, GRW ;

HASHIMOTO, SA ;

MORRISON, W ;

NELSON, J ;

GOODIN, DS ;

MASSA, SM ;

GUTTERIDGE, E ;

ARNASON, BGW ;

NORONHA, A ;

REDER, AT ;

MARTIA, R ;

EBERS, GC ;

RICE, GPA ;

LESAUX, J ;

JOHNSON, KP ;

PANITCH, HS ;

BEVER, CT ;

CONWAY, K ;

WALLENBERG, JC ;

BEDELL, L ;

VANDENNOORT, S ;

WEINSHENKER, B ;

WEISS, W ;

REINGOLD, S ;

PACHNER, A ;

TAYLOR, W .

NEUROLOGY, 1993, 43 (04) :655-661

[7]

Ebers G, 1999, NEUROLOGY, V53, P679

[8] Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis [J].

Ebers, GC ;

Rice, G ;

Lesaux, J ;

Paty, D ;

Oger, J ;

Li, DKB ;

Beall, S ;

Devonshire, V ;

Hashimoto, S ;

Hooge, J ;

Kastrukoff, L ;

Krieger, C ;

Mezei, M ;

Seland, P ;

Vorobeychi, G ;

Morrison, W ;

Nelson, J ;

Freedman, MS ;

Chrisie, S ;

Nelson, R ;

Rabinovitch, H ;

Freedman, C ;

Hartung, HP ;

Rieckmann, P ;

Archelos, J ;

Jung, S ;

Weilbach, F ;

Flachenecke, P ;

Sauer, J ;

Hommes, O ;

Jongen, P ;

Brouwer, S ;

McLeod, J ;

Pollard, J ;

Ng, R ;

Sandberg-Wollheim, M ;

Källén, K ;

Nilsson, P ;

Ekberg, R ;

Lundgren, A ;

Jadbäck, G ;

Wikström, J ;

Multanen, J ;

Valjakka, M ;

Carton, H ;

Lissoir, F ;

Declerq, I ;

Vieren, M ;

Peeters, E ;

Dubois, B .

LANCET, 1998, 352 (9139) :1498-1504

[9] Population based cost utility study of interferon beta-1b in secondary progressive multiple sclerosis [J].

Forbes, RB ;

Lees, A ;

Waugh, N ;

Swingler, RJ .

BMJ-BRITISH MEDICAL JOURNAL, 1999, 319 (7224) :1529-1533

[10] LOW-DOSE (7.5-MG) ORAL METHOTREXATE REDUCES THE RATE OF PROGRESSION IN CHRONIC PROGRESSIVE MULTIPLE-SCLEROSIS [J].

GOODKIN, DE ;

RUDICK, RA ;

MEDENDORP, SV ;

DAUGHTRY, MM ;

SCHWETZ, KM ;

FISCHER, J ;

VANDYKE, C .

ANNALS OF NEUROLOGY, 1995, 37 (01) :30-40

← 1 2 3 →